Generic Name: Pegfilgrastim
Study IDStudied Indication or DiseasePhaseStudy TitleSynopsis
20020175Prevent neutropenia in subjects receiving FOIL (5-fluorouracil [5-FU], oxaliplatin, irinotecan, leucovorin), FOLFOX (5-FU, oxaliplatin, leucovorin), or FOLFIRI (5-FU, irinotecan, leucovorin) for local2

Chemotherapy Administered Every 2 Weeks With or Without a Single Injection of Pegfilgrastim as First- or Second-Line Treatment in Subjects With Locally Advanced or Metastatic Colon Cancer

20080259Colorectal Cancer3A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Administered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab and Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLFOX) or 5-fluorouracil, Irinotecan, Leucovorin (FOLFIRI)
20110146Chemotherapy Induced NeutropeniaObservationa;Study to Investigate Which Clinical Risk Factors Are Considered by Physicians When Conducting Overall Febrile Neutropenia Risk Assessments for Patients Receiving Chemotherapy With an Intermediate (10% – 20%) Febrile Neutropenia Risk